Your browser is no longer supported. Please, upgrade your browser.
Atea Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.14 Insider Own18.48% Shs Outstand82.44M Perf Week-13.72%
Market Cap1.82B Forward P/E1.24 EPS next Y17.25 Insider Trans0.00% Shs Float73.96M Perf Month-62.46%
Income-10.90M PEG- EPS next Q-0.06 Inst Own58.10% Short Float5.75% Perf Quarter-75.23%
Sales48.60M P/S37.49 EPS this Y23.60% Inst Trans0.17% Short Ratio7.28 Perf Half Y-31.29%
Book/sh6.65 P/B3.21 EPS next Y7742.27% ROA-3.90% Target Price- Perf Year-
Cash/sh9.95 P/C2.14 EPS next 5Y- ROE-12.30% 52W Range19.70 - 94.17 Perf YTD-48.97%
Dividend- P/FCF- EPS past 5Y- ROI-2.00% 52W High-77.36% Beta-
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low8.22% ATR3.46
Employees39 Current Ratio2.70 Sales Q/Q- Oper. Margin- RSI (14)15.70 Volatility10.11% 10.49%
OptionableYes Debt/Eq0.00 EPS Q/Q244.20% Profit Margin-22.50% Rel Volume1.81 Prev Close22.02
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume583.80K Price21.32
Recom1.70 SMA20-43.39% SMA50-61.21% SMA200-58.01% Volume1,056,530 Change-3.18%
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
May-06-21 07:00AM  
Apr-29-21 06:44AM  
Apr-22-21 06:25AM  
Apr-21-21 05:15AM  
Apr-16-21 06:49AM  
Apr-14-21 09:40AM  
Apr-08-21 01:24AM  
Mar-31-21 02:00AM  
Mar-30-21 04:01PM  
Mar-23-21 07:00AM  
Mar-06-21 07:00AM  
Feb-19-21 08:30AM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-04-21 07:00AM  
Jan-30-21 01:30AM  
Jan-26-21 06:20AM  
Jan-19-21 07:00AM  
Dec-21-20 08:48AM  
Dec-18-20 08:00AM  
Nov-25-20 07:00AM  
Nov-20-20 07:54PM  
Nov-06-20 08:00AM  
Nov-03-20 04:01PM  
Nov-01-20 09:29PM  
Oct-29-20 08:00PM  
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.